

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CK Life Sciences Int'l., (Holdings) Inc.

長江生命科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0775)

**APPOINTMENT OF EXECUTIVE DIRECTOR,
VICE PRESIDENT AND CHIEF EXECUTIVE OFFICER
AND
RE-DESIGNATION OF EXECUTIVE DIRECTOR**

The Board of Directors (the “**Board**”) of CK Life Sciences Int'l., (Holdings) Inc. (the “**Company**”) announces that with effect from 20 September 2024, Mr. Lance Richard Lee Yuen (“**Mr. Yuen**”) is appointed as Executive Director, Vice President and Chief Executive Officer of the Company; and Mr. Yu Ying Choi, Alan Abel (“**Mr. Yu**”), an Executive Director, is re-designated from his current position of Vice President and Chief Executive Officer to Deputy Chairman of the Company.

Set out below are the biographical profiles of Mr. Yuen and Mr. Yu:

Mr. Lance Richard LEE YUEN

Mr. Lance Richard Lee Yuen, aged 59, is Vice President and Chief Executive Officer of the Company, and a member of the Executive Committee. Mr. Yuen joined the Group in September 2024. Mr. Yuen holds a Bachelor of Arts degree and a Master of Business Administration degree. Mr. Yuen has over 35 years of leadership experience in multinational healthcare, packaged goods, and pharmaceutical companies in United States, Canada, Hong Kong, Japan and China. Prior to joining the Group, Mr. Yuen was Asia-Pacific President and a member of the Executive Committee of the Consumer Health division within Bayer, a German multinational company which is one of the largest pharmaceutical, agricultural, and biomedical companies in the world.

Mr. Yuen does not have any relationship with any other Directors, senior management or substantial or controlling shareholders of the Company. He does not have any interest in shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (“**SFO**”). Pursuant to the Company’s Articles of Association, Mr. Yuen will hold office until the next general meeting of the Company when he will be eligible for re-election. The term of Mr. Yuen’s service as an Executive Director of the Company is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the provisions of the Articles of Association of the Company. The Director’s fee of Mr. Yuen as an Executive Director, Vice President and Chief Executive Officer of the Company under his appointment letter is HK\$75,000 per annum. Such fees are subject to review from time to time and proration for any incomplete year of service. The emoluments of Directors are determined by reference to the Company’s performance and profitability, as well as the prevailing market conditions.

Save as disclosed herein, there are no other matters concerning Mr. Yuen’s appointment that need to be brought to the attention of the shareholders of the Company nor any information to be disclosed pursuant to the requirements of Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

Mr. YU Ying Choi, Alan Abel

Mr. YU Ying Choi, Alan Abel, aged 69, is Deputy Chairman of the Company. Mr. Yu has been a member of the Executive Committee of the Company since February 2021. Mr. Yu acted as the Vice President and Chief Executive Officer of the Company from September 2020 to September 2024 and acted as the Vice President and Chief Operating Officer of the Company from June 2002 to September 2020. He holds a Bachelor of Arts degree and a Master's degree in Business Administration and is a fellow member of The Hong Kong Institute of Directors.

Mr. Yu does not have any relationship with any other Directors, senior management or substantial or controlling shareholders of the Company. Mr. Yu has a personal interest of 2,250,000 shares of the Company within the meaning of Part XV of the SFO. The Director's fee of Mr. Yu as an Executive Director and Deputy Chairman of the Company under his appointment letter is HK\$75,000 per annum. The emoluments of Directors are determined by reference to the Company's performance and profitability, as well as the prevailing market conditions.

Save as disclosed above, there are no other matters concerning Mr. Yu's re-designation to Deputy Chairman of the Company that need to be brought to the attention of the shareholders of the Company nor any information to be disclosed pursuant to the requirements of Rule 13.51(2) of the Listing Rules.

By Order of the Board
CK Life Sciences Int'l., (Holdings) Inc.
Eirene Yeung
Company Secretary

Hong Kong, 20 September 2024

As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel, Mr. Lance Richard Lee Yuen and Dr. Toh Kean Meng, Melvin; and the Non-executive Directors are Mr. Peter Peace Tulloch, Mrs. Kwok Eva Lee (Independent Non-executive Director), Mr. Kwan Kai Cheong (Independent Non-executive Director), Mr. Paul Joseph Tighe (Independent Non-executive Director) and Mr. Donald Jeffrey Roberts (Independent Non-executive Director).